NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Obinutuzumab for treating lupus nephritis ID6420

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company • Roche (obinutuzumab) Patient/carer groups • Arthritis Action • Arthritis & Musculoskeletal Alliance • Genetic Alliance UK • Gene People • Hibbs Lupus Trust • Kidney Care UK • Lupus Trust • Lupus UK • National Kidney Federation • National Rheumatoid Arthritis Society • Polycystic Kidney Disease Charity • South Asian Health Foundation • Specialised Healthcare Alliance Healthcare professional groups • Association of Renal Industries • Association of Renal Technologists • British Association of Urological Nurses • British Association of Urological Surgeons • British Geriatrics Society • British Isles Lupus Assessment Group • British Society for Allergy and Clinical Immunology • British Society for Haematology • British Society for Rheumatology • British Society of Haemostasis and Thrombosis • Clinical Leaders of Thrombosis • Primary Care Rheumatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • NHS England Specialised Rheumatology Clinical Reference Group • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Possible comparator companies • Aspen (azathioprine) • Astellas Pharma (tacrolimus) • Baxter Healthcare (cyclophosphamide) • Chiesi (tacrolimus) • Celltrion Healthcare (rituximab) • Dexcel Pharm (ciclosporin) • Leo Laboratories (tacrolimus) • Mylan (azathioprine, ciclosporin) • Nova Laboratories (azathioprine) • Novartis (ciclosporin, mycophenolic acid) • Otsuka Pharmaceuticals (voclosporin) • Pfizer (rituximab)

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
• Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists • Society for Vascular Technology • Society of Vascular Nurses • UK Clinical Pharmacy Association • UK Kidney Association • UK Renal Pharmacy Group • United Kingdom Primary Immunodeficiency Network • Urology Foundation • Vascular Society of Great Britain and Ireland <u>Others</u> • Department of Health and Social Care • NHS England	• Roche (rituximab, mycophenolate mofetil) • Rosemont Pharmaceuticals (mycophenolate mofetil) • Sandoz (cyclophosphamide, mycophenolic acid, rituximab, tacrolimus) • Santen (ciclosporin) • Strides Pharma (azathioprine) • Teva Pharma (mycophenolate mofetil) • Tillomed Laboratories (azathioprine, mycophenolate mofetil) <u>Relevant research groups</u> • Cochrane Kidney and Transplant Group • Genomics England • Kidney Research UK • MRC Clinical Trials Unit • National Institute for Health Research <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

